Product Revenue Reserves and Allowances (Tables)

12 Months Ended

Dec. 31, 2023

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

Net product revenues by product for the years ended December 31, 2023 and 2022 were as follows (in thousands):

	Year Ended		Year Ended
	December 31,		December 31,
	2023		2022
YUTIQ (A)	$	14,232	$	28,329
DEXYCU (B)		—		11,576
Total product sales, net	$	14,232	$	39,905

(A)Includes approximately $452 and $343 of revenue from YUTIQ® product sales to Ocumension Therapeutics under a supply agreement for the years ended December 31, 2023 and 2022, respectively.

(B)Includes approximately $82 and $20 of revenue from DEXYCU® product sales to Ocumension Therapeutics under a supply agreement for the years ended December 31, 2023 and 2022, respectively.

Product Revenue Allowance and Reserves

The following table summarizes activity in each of the product revenue allowance and reserve categories for the years ended December 31, 2023 and 2022 (in thousands):

	Chargebacks, Discounts and Fees			Government and Other Rebates			Returns			Total
Beginning balance at January 1, 2023	$	859		$	158		$	871		$	1,888
Provision related to sales in the current year		1,612			—			25			1,637
Adjustments related to prior period sales		65			(55	)		(54	)		(44	)
Deductions applied and payments made		(2,453	)		(103	)		(165	)		(2,721	)
Ending balance at December 31, 2023	$	83		$	—		$	677		$	760

As of December 31, 2023, returns, chargebacks, discounts and fees, and rebates are recorded as a component of accrued expenses on the consolidated balance sheets (see Note 7)

	Chargebacks, Discounts and Fees			Government and Other Rebates			Returns			Total
Beginning balance at January 1, 2022	$	1,153		$	1,821		$	379		$	3,353
Provision related to sales in the current year		10,970			5,520			816			17,306
Adjustments related to prior period sales		—			—			—			—
Deductions applied and payments made		(11,264	)		(7,183	)		(324	)		(18,771	)
Ending balance at December 31, 2022	$	859		$	158		$	871		$	1,888

As of December 31, 2022, returns are recorded as a reduction of accounts receivable on the consolidated balance sheets. Chargebacks, discounts and fees, and rebates are recorded as a component of accrued expenses on the consolidated balance sheets (see Note 7).